IMIPENEM AND CILASTATIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Imipenem And Cilastatin, and when can generic versions of Imipenem And Cilastatin launch?
Imipenem And Cilastatin is a drug marketed by Acs Dobfar, Hospira Inc, and Hq Spclt Pharma. and is included in four NDAs.
The generic ingredient in IMIPENEM AND CILASTATIN is cilastatin sodium; imipenem. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the cilastatin sodium; imipenem profile page.
Summary for IMIPENEM AND CILASTATIN
US Patents: | 0 |
Applicants: | 3 |
NDAs: | 4 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 12 |
Clinical Trials: | 43 |
Patent Applications: | 178 |
Formulation / Manufacturing: | see details |
DailyMed Link: | IMIPENEM AND CILASTATIN at DailyMed |
Recent Clinical Trials for IMIPENEM AND CILASTATIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Meiji Seika Pharma Co., Ltd. | Phase 3 |
University of Pittsburgh Medical Center | Phase 4 |
Merck Sharp & Dohme LLC | Phase 4 |
Pharmacology for IMIPENEM AND CILASTATIN
Drug Class | Penem Antibacterial Renal Dehydropeptidase Inhibitor |
Mechanism of Action | Dipeptidase Inhibitors |